Gene Therapy for Atrial Fibrillation in Heart Failure

R. Arora*

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Atrial fibrillation (AF) is the most common arrhythmia and a major cause of morbidity and mortality in an aging population. Unfortunately, current treatments for AF are suboptimal, in large part because the molecular mechanisms underlying AF are not well understood. Recent advances in our understanding of the AF disease state have led to the preclinical development of gene-based therapies that are targeted to key molecular mechanisms involved in the genesis and maintenance of AF.

Original languageEnglish (US)
Pages (from-to)200-202
Number of pages3
JournalClinical pharmacology and therapeutics
Volume102
Issue number2
DOIs
StatePublished - Aug 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Gene Therapy for Atrial Fibrillation in Heart Failure'. Together they form a unique fingerprint.

  • Cite this